Single Site, Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors
Latest Information Update: 15 Feb 2020
At a glance
- Drugs Xiliertinib (Primary)
- Indications Gastric cancer; Lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 31 May 2016 Status changed from recruiting to completed.
- 19 Nov 2012 New trial record